NASDAQ
25.11.25 | 21:58
2,475 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | C4 Therapeutics files $400M mixed shelf offering | 2 | Seeking Alpha | ||
| 06.11. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.10. | C4 Therapeutics prices $125M equity offering with warrants | 6 | Seeking Alpha | ||
| 16.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering | 5 | GlobeNewswire (USA) | ||
| 16.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 01.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma | 140 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 23.09. | C4 Therapeutics stock price target raised to $10 by Wells Fargo on positive data | 10 | Investing.com | ||
| 23.09. | C4 Therapeutics: Wells Fargo verdoppelt Kursziel nach positiven Studiendaten | 5 | Investing.com Deutsch | ||
| 22.09. | Forecasting The Future: 4 Analyst Projections For C4 Therapeutics | 4 | Benzinga.com | ||
| 22.09. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | Myelom-Medikament von C4 Therapeutics zeigt 50-prozentige Ansprechrate in Studie | 1 | Investing.com Deutsch | ||
| 20.09. | C4 Therapeutics Reports Promising Phase 1 Results For Cemsidomide In R/R Multiple Myeloma | 1 | RTTNews | ||
| 20.09. | C4 Therapeutics' myeloma drug shows 50% response rate in trial | 2 | Investing.com | ||
| 20.09. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09. | Barclays bestätigt "Overweight"-Rating für C4 Therapeutics | 1 | Investing.com Deutsch | ||
| 16.09. | C4 Therapeutics stock rating reiterated as Overweight by Barclays | 3 | Investing.com | ||
| 16.09. | Why C4 Therapeutics Stock Crushed the Market on Monday | 3 | The Motley Fool | ||
| 15.09. | Stephens-Upgrade beflügelt C4 Therapeutics-Aktie mit über 125 % Kurspotenzial | 5 | Investing.com Deutsch |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,540 | -1,91 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,000 | +0,12 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 21,600 | -6,09 % | Celldex Therapeutics, Inc.: Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer | HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,800 | -1,10 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,075 | -2,49 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| NEOVACS | 0,023 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,810 | +7,58 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ULTRAGENYX | 28,800 | -0,69 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| GYRE THERAPEUTICS | 6,450 | -3,73 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update | Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million... ► Artikel lesen | |
| BIOMEA FUSION | 1,025 | +1,49 % | Biomea Fusion, Inc.: Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations | Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,100 | +0,83 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567... ► Artikel lesen | |
| GOSSAMER BIO | 2,860 | +1,27 % | Respira Therapeutics, Inc.: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital | - Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and... ► Artikel lesen | |
| JANUX THERAPEUTICS | 34,740 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,680 | -1,93 % | 4D Molecular Therapeutics, Inc.: 4DMT Appoints Kristian Humer as Chief Financial Officer | EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,220 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 | Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,475 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.